Financial results for the half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vanta Bioscience reported unaudited H1 FY26 (ended September 30, 2025) results, approved by the Board on November 14, 2025. Standalone revenue from operations fell sharply to Rs. 30.18 lakhs from Rs. 80.09 lakhs in H1 FY25, a drop of about 62%. Standalone net loss widened to Rs. 181.32 lakhs (EPS of Rs. -2.55) versus Rs. 129.34 lakhs (EPS Rs. -2.05) a year ago. Consolidated results also showed a net loss of Rs. 181.89 lakhs, though better than the Rs. 206.88 lakhs loss in H1 FY25. The auditor (Mathesh & Ramana) issued an unmodified limited review report on both standalone and consolidated statements. Operating cash flow was deeply negative at Rs. -321.78 lakhs (standalone), funded by fresh borrowings and share capital infusion. Total borrowings stood at around Rs. 3,057 lakhs against equity of Rs. 1,932 lakhs, keeping debt-equity above 1.5x.
Shareholders should note continued revenue erosion, widening losses, and negative operating cash flow, though fresh equity infusion and borrowings kept the company funded. The weak top-line and high leverage are likely to weigh on the stock, while any sign of revenue recovery remains the key catalyst to watch.